ClinicalTrials.gg
Not yet recruitingNCT07924930Updated Nov 9, 2026

A Study of Tersolisib (LY4064809) in Participants With Kidney Impairment Compared With Participants With Normal Kidney Function

A Phase 1 interventional study of Tersolisib in Renal Insufficiency and Healthy Participant, sponsored by Scorpion Therapeutics, a wholly owned subsidiary of Eli Lilly and Company. Not yet recruiting at 2 sites in United States. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Scorpion Therapeutics, a wholly owned subsidiary of Eli Lilly and Company (part of Eli Lilly and Company) · Phase 1, Interventional, and Basic science

Updated Nov 9, 2026Newly registeredGo to Updates ↓
Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

The main purpose of this study is to measure how much tersolisib gets into the bloodstream and how long it takes the body to eliminate it in participants with kidney impairment compared to those with normal kidney function. The safety of tersolisib will also be evaluated.

For each participant, the study will last about 7 weeks including a 14-night stay in the clinical research unit (CRU) and one follow-up telephone call.

02

Conditions studied

  • Renal Insufficiency
  • Healthy Participant

Keywords

  • Chronic Kidney Disease
03

In context

Renal Insufficiency

1,409 studies on the registry are indexed under Renal Insufficiency; 143 are open to participants now.

This study's planned enrollment of 32 is below the median of 40 across 1,058 interventional studies indexed under Renal Insufficiency.

Browse Renal Insufficiency studies →

Lead sponsor

Scorpion Therapeutics, a wholly owned subsidiary of Eli Lilly and Company is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

First submitted after Scorpion Therapeutics became part of Eli Lilly and Company.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a (BMI) within the range 19 to 42 kilograms per square meter (kg/m²), inclusive
  • Participants assigned male at birth (AMAB) who agree to follow guidance or participants assigned female at birth (AFAB) who are individuals not of (INOCBP)

Participants with Normal Renal Function:

  • Are healthy with normal renal function, defined as estimated (eGFR) greater than or equal to 90 milliliters per minute (mL/min) at screening

Participants with Renal Impairment:

  • Have moderate renal impairment, defined as eGFR greater than or equal to 30 and less than 60 mL/min, or severe renal impairment, defined as eGFR less than 30 mL/min and not requiring dialysis
  • Are on stable doses of prescription or over-the-counter medications for the management of chronic kidney disease
  • Have acceptable blood pressure as defined by systolic blood pressure less than 160 millimeters of mercury (mmHg) and diastolic blood pressure less than 95 mmHg, as well as acceptable pulse rate, defined as no less than 50 beats per minute (bpm) and no greater than 100 bpm.

Exclusion criteria

Exclusion Criteria:

  • Have history of chronic liver disease, or any evidence for hepatic impairments, or

    • (ALT) or aspartate aminotransferase (AST) greater than 1.5 times (x) upper limit normal () or
    • total (TBL) greater than 1.5 x ULN
  • Have a current, functional renal transplant
  • Have a history or presence of any of the following conditions: metabolic, biliary, gastrointestinal, hematological, neurological diseases, active cardiovascular (CV) disease or history of myocardial infarction within 3 months of planned dose of tersolisib, or 12-lead (ECG) abnormalities that are clinically significant at screening, admission or predose.
  • Have a clinically significant history of multiple or severe drug reactions, or drug allergies, such as anaphylaxis, hepatotoxicity, or treatment with or epinephrine.
  • Have a history of a major surgical procedure within 30 days prior to screening.
  • Have been diagnosed with, or treated for, within 5 years prior to screening with the exception of curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and curatively resected in situ carcinoma of the cervix.
  • Have evidence of (HIV) infection or positive HIV-1 and HIV-2 antibodies.
  • Have a current infection with Virus (HCV), that is, positive for HCV Ribonucleic Acid (RNA).
  • Have a current infection with Virus (HBV), that is, positive test for Hepatitis B Surface Antigen (HBsAg) or polymerase chain reaction positive for HBV DNA
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    Tersolisib Group 1 (Normal Renal Function)

    Tersolisib administered orally to participants with normal renal function

    Drug: Tersolisib

  • Experimental
    Tersolisib Group 2 (Severe Renal Impairment)

    Tersolisib administered orally to participants with severe renal impairment

    Drug: Tersolisib

  • Experimental
    Tersolisib Group 3 (Moderate Renal Impairment, Optional)

    Tersolisib administered orally to participants with moderate renal impairment

    Drug: Tersolisib

Interventions

  • Administered orally

    Also known as: LY4064809, STX-478

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of Tersolisib

    Time frame: Predose on Day 1 through Day 14

  2. PK: Area Under the Concentration Versus Time Curve (AUC) of Tersolisib

    Time frame: Predose on Day 1 through Day 14

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Aug 2027, 9 months later.

Of 212 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 9 months is above that.

Counting every sponsor, half of 230 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2026
First posted
Nov 9, 2026
StartEst.
Nov 2026
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2027
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07924930
Responsible party
Sponsor
First posted
Nov 9, 2026
Start date
Nov 2026 (estimated)
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Nov 9, 2026

Study contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Contact
LillyTrials@Lilly.com
1-317-615-4559
Physicians interested in becoming principal investigators please contact
Contact
clinical_inquiry_hub@lilly.com
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: STX-478

Start the discussion